BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28860820)

  • 1. Safety and efficacy of nimotuzumab combined with chemoradiotherapy in Chinese patients with locally advanced cervical cancer.
    Chen YF; Tang WB; Pan XX; Wu CR; Cao Y; Yang W
    Onco Targets Ther; 2017; 10():4113-4119. PubMed ID: 28860820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.
    Cetina L; Crombet T; Jiménez-Lima R; Zapata S; Ramos M; Avila S; Coronel J; Charco E; Bojalil R; Astudillo H; Bazán B; Dueñas-González A
    Cancer Biol Ther; 2015; 16(5):684-9. PubMed ID: 25802932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China.
    Tian X; Xuan Y; Wu R; Gao S
    Cancer Manag Res; 2020; 12():3323-3329. PubMed ID: 32494195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer.
    Li J; Li Y; Wang H; Shen L; Wang Q; Shao S; Shen Y; Xu H; Liu H; Cai R; Feng W
    BMC Cancer; 2023 Jan; 23(1):51. PubMed ID: 36641433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer.
    Cao Y; Deng L; Lian S; Jiang Y
    J BUON; 2019; 24(5):2013-2019. PubMed ID: 31786869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
    Yamamoto N; Harada H; Okamoto I; Masuda N; Hayakawa K; Satouchi M; Soejima T; Nishio M; Kozuka T; Takeda K; Tanaka M; Seto T; Sasaki T; Tsubouchi H; Kakurai Y; Nishimura Y; Nakagawa K
    Clin Lung Cancer; 2021 Mar; 22(2):134-141. PubMed ID: 33518480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nimotuzumab and PF induction chemotherapy combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma.
    Gao M; Yuan T; Zhang F
    J BUON; 2021; 26(1):116-123. PubMed ID: 33721441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
    Monk BJ; Toita T; Wu X; Vázquez Limón JC; Tarnawski R; Mandai M; Shapira-Frommer R; Mahantshetty U; Del Pilar Estevez-Diz M; Zhou Q; Limaye S; Godinez FJR; Oppermann Kussler C; Varga S; Valdiviezo N; Aoki D; Leiva M; Lee JY; Sulay R; Kreynina Y; Cheng WF; Rey F; Rong Y; Ke G; Wildsmith S; Lloyd A; Dry H; Tablante Nunes A; Mayadev J
    Lancet Oncol; 2023 Dec; 24(12):1334-1348. PubMed ID: 38039991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy.
    Ao M; Li P; Sun D; Li X; Xu S; Hao Y
    J Obstet Gynaecol; 2023 Dec; 43(1):2179915. PubMed ID: 37001548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.
    Qin S; Li J; Bai Y; Wang Z; Chen Z; Xu R; Xu J; Zhang H; Chen J; Yuan Y; Liu T; Yang L; Zhong H; Chen D; Shen L; Hao C; Fu D; Cheng Y; Yang J; Wang Q; Qin B; Pan H; Zhang J; Bai X; Zheng Q
    J Clin Oncol; 2023 Nov; 41(33):5163-5173. PubMed ID: 37647576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer.
    Qi S; Mao Y; Jiang M
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1115-1123. PubMed ID: 31502113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of PD-1 inhibitor combined with concurrent chemoradiotherapy in locally advanced cervical cancer with pelvic and/or para-aortic lymph node metastases: a retrospective cohort study.
    Liu C; Ran X; Wang Z; Zhang K
    Chin Clin Oncol; 2023 Aug; 12(4):38. PubMed ID: 37699603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
    Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
    J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study.
    Hu J; Chen Z; Lv J; Zheng Z; Bei Y; Chen X; Zheng L; Song W; Xu Y
    Front Oncol; 2022; 12():905422. PubMed ID: 35898885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of nimotuzumab combined with chemoradiotherapy in the treatment of locally advanced cervical cancer.
    Zhang L; Jiang Y; Jiang P; Chen Z; Cui H; Zhang Y
    Ann Transl Med; 2022 Dec; 10(24):1322. PubMed ID: 36660627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
    Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
    BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma.
    Huang J; Zou Q; Qian D; Zhou L; Yang B; Chu J; Pang Q; Wang K; Zhang F
    Onco Targets Ther; 2017; 10():5835-5841. PubMed ID: 29263680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
    Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
    BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma.
    Ang MK; Montoya JE; Tharavichitkul E; Lim C; Tan T; Wang LY; Wee J; Soong YL; Fong KW; Ng QS; Tan DS; Toh CK; Tan EH; Lim WT
    Head Neck; 2021 May; 43(5):1641-1651. PubMed ID: 33547683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.